Article info
Review
Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions
- Correspondence to Michel Michaelides, Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK; michel.michaelides{at}ucl.ac.uk
Citation
Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions
Publication history
- Received November 19, 2020
- Revised January 20, 2021
- Accepted February 23, 2021
- First published March 19, 2021.
Online issue publication
February 18, 2022
Article Versions
- Previous version (18 February 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.